Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 25.43% is 273% above its 5-year average of -14.74%, near the high end of its 5-year range (-35.78%–25.43%).
401.08% above its 12-month average of 5.08%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -5.06%.
RETURN ON ASSETS (ROA)
25.43%
RETURN ON ASSETS (ROA) AVG TTM
5.08%
RETURN ON ASSETS (ROA) AVG 3Y
-10.27%
RETURN ON ASSETS (ROA) AVG 5Y
-14.74%
RETURN ON ASSETS (ROA) AVG 10Y
-31.09%
RETURN ON ASSETS (ROA) AVG 15Y
-29.40%
RETURN ON ASSETS (ROA) AVG 20Y
-30.87%
CURRENT VS TTM AVG
+401.08%
CURRENT VS 3Y AVG
+347.55%
CURRENT VS 5Y AVG
+272.52%
CURRENT VS 10Y AVG
+181.78%
CURRENT VS 15Y AVG
+186.50%
CURRENT VS 20Y AVG
+182.39%
SECTOR MEDIAN · HEALTHCARE
-26.90%
median of 504 covered companies
CURRENT VS SECTOR MEDIAN
+194.54%
vs the sector median at left
Compugen Ltd.
Market Cap
$218.42M
Return on Assets (ROA)
25.43%
TTM Avg
5.08%
3Y Avg
-10.27%
5Y Avg
-14.74%
Market Cap
$220.94M
Return on Assets (ROA)
-58.10%
TTM Avg
-37.08%
3Y Avg
-28.02%
5Y Avg
-25.91%
Market Cap
$228.41M
Return on Assets (ROA)
-28.91%
TTM Avg
-2.34%
3Y Avg
-20.04%
5Y Avg
-20.00%
Market Cap
$206.61M
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$202.05M
Return on Assets (ROA)
-44.41%
TTM Avg
-56.25%
3Y Avg
-49.77%
5Y Avg
-92.23%
Market Cap
$236.56M
Return on Assets (ROA)
-29.12%
TTM Avg
-42.23%
3Y Avg
-51.88%
5Y Avg
-48.35%
Market Cap
$239.45M
Return on Assets (ROA)
-23.80%
TTM Avg
-23.59%
3Y Avg
-108.30%
5Y Avg
-108.30%
Market Cap
$239.89M
Return on Assets (ROA)
-8.99%
TTM Avg
-7.90%
3Y Avg
-14.69%
5Y Avg
-13.78%
Market Cap
$192.97M
Return on Assets (ROA)
-78.16%
TTM Avg
-23.70%
3Y Avg
-68.26%
5Y Avg
-50.80%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Compugen Ltd. (CGEN) | $218.42M | 25.43% | 5.08% | -10.27% | -14.74% |
| Alector, Inc. (ALEC)vs › | $220.94M | -58.10% | -37.08% | -28.02% | -25.91% |
| Keros Therapeutics, Inc. (KROS)vs › | $228.41M | -28.91% | -2.34% | -20.04% | -20.00% |
| Electra Therapeutics Inc. (ETRA)vs › | $206.61M | N/A | N/A | N/A | N/A |
| AN2 Therapeutics, Inc. (ANTX)vs › | $202.05M | -44.41% | -56.25% | -49.77% | -92.23% |
| Biodesix, Inc. (BDSX)vs › | $236.56M | -29.12% | -42.23% | -51.88% | -48.35% |
| BioAge Labs Inc. (BIOA)vs › | $239.45M | -23.80% | -23.59% | -108.30% | -108.30% |
| High Tide Inc. (HITI)vs › | $239.89M | -8.99% | -7.90% | -14.69% | -13.78% |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $192.97M | -78.16% | -23.70% | -68.26% | -50.80% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $244.25M | -8.48% | -16.43% | -20.20% | -32.31% |
ROA
25.4%
ROE
39.7%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 22.53% |
| 2024-12-31 | -12.38% |
| 2023-12-31 | -15.46% |
| 2022-12-31 | -35.78% |
| 2021-12-31 | -25.88% |
| 2020-12-31 | -21.47% |
| 2019-12-31 | -50.85% |
| 2018-12-31 | -42.50% |
| 2017-12-31 | -95.66% |
| 2016-12-31 | -44.29% |
| 2015-12-31 | -20.30% |
| 2014-12-31 | -9.66% |
| 2013-12-31 | -24.83% |
| 2012-12-31 | -47.14% |
| 2011-12-31 | -41.28% |
| 2010-12-31 | -19.76% |
| 2009-12-31 | -12.69% |
| 2008-12-31 | -87.95% |
| 2007-12-31 | -55.91% |
| 2006-12-31 | -42.20% |
| 2005-12-31 | -33.20% |
| 2004-12-31 | -24.79% |
| 2003-12-31 | -16.94% |
| 2002-12-31 | -15.80% |
| 2001-12-31 | -17.35% |
| 2000-12-31 | -13.70% |
| 1999-12-31 | -52.38% |
